The NPM1 mutation type has no impact on survival in cytogenetically normal AML

Friederike Pastore; Philipp A Greif; Stephanie Schneider; Bianka Ksienzyk; Gudrun Mellert; Evelyn Zellmeier; Jan Braess; Cristina M Sauerland; Achim Heinecke; Utz Krug; Wolfgang E Berdel; Thomas Buechner; Bernhard Woermann; Wolfgang Hiddemann; Karsten Spiekermann

doi:10.1371/journal.pone.0109759

The NPM1 mutation type has no impact on survival in cytogenetically normal AML

PLoS One. 2014 Oct 9;9(10):e109759. doi: 10.1371/journal.pone.0109759. eCollection 2014.

Authors

Affiliations

¹ Laboratory for Leukemia Diagnostics, Dept. of Internal Medicine III, University Hospital Munich Großhadern, Ludwig-Maximilian-University (LMU), Munich, Germany; Clinical Cooperative Group Pathogenesis of Acute Myeloid Leukemia, Helmholtz Zentrum München, German Research Center for Environmental Health, Munich, Germany; German Cancer Consortium (DKTK), Heidelberg, Germany; German Cancer Research Center (DKFZ), Heidelberg, Germany.
² Laboratory for Leukemia Diagnostics, Dept. of Internal Medicine III, University Hospital Munich Großhadern, Ludwig-Maximilian-University (LMU), Munich, Germany.
³ Dept. of Oncology and Hematology, Krankenhaus Barmherzige Brüder, Regensburg, Germany.
⁴ Institute of Biostatistics and Clinical Research, University of Muenster, Muenster, Germany.
⁵ Dept. of Internal Medicine A, Hematology and Oncology, University of Muenster, Muenster, Germany.
⁶ German Society of Hematology and Oncology, Berlin, Germany.

Abstract

NPM1 mutations represent frequent genetic alterations in patients with acute myeloid leukemia (AML) associated with a favorable prognosis. Different types of NPM1 mutations have been described. The purpose of our study was to evaluate the relevance of different NPM1 mutation types with regard to clinical outcome. Our analyses were based on 349 NPM1-mutated AML patients treated in the AMLCG99 trial. Complete remission rates, overall survival and relapse-free survival were not significantly different between patients with NPM1 type A or rare type mutations. The NPM1 mutation type does not seem to play a role in risk stratification of cytogenetically normal AML.

Trial registration: ClinicalTrials.gov NCT00266136.

Publication types

Randomized Controlled Trial

MeSH terms

Adult
Aged
Antineoplastic Agents / therapeutic use*
Cytarabine / therapeutic use
Daunorubicin / therapeutic use
Female
Gene Expression
Humans
Induction Chemotherapy / methods
Karyotyping
Leukemia, Myeloid, Acute / diagnosis
Leukemia, Myeloid, Acute / drug therapy*
Leukemia, Myeloid, Acute / genetics*
Leukemia, Myeloid, Acute / mortality
Male
Middle Aged
Mitoxantrone / therapeutic use
Mutation*
Nuclear Proteins / genetics*
Nucleophosmin
Prognosis
Remission Induction
Risk Factors
Survival Analysis
Thioguanine / therapeutic use
Treatment Outcome
fms-Like Tyrosine Kinase 3 / genetics

Substances

Antineoplastic Agents
NPM1 protein, human
Nuclear Proteins
Cytarabine
Nucleophosmin
Mitoxantrone
FLT3 protein, human
fms-Like Tyrosine Kinase 3
Thioguanine
Daunorubicin

Associated data

ClinicalTrials.gov/NCT00266136

Grants and funding

The authors have no support or funding to report.